Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer

Area of Science:

• Molecular oncology
• Epigenetics
• Cancer genomics

Background:

• The Polycomb group (PcG) protein EZH2 is implicated in oncogenesis, but its precise mechanisms and key targets remain incompletely understood.
• Identifying EZH2 targets is crucial for understanding its role in cancer development and progression.

Purpose of the Study:

• To identify and validate key EZH2 targets using an integrated multi-omics approach.
• To elucidate the functional role of EZH2-mediated regulation of ADRB2 in prostate cancer.

Main Methods:

• Integration of in vitro cell line data, in vivo tumor profiling, and genome-wide EZH2 location data.
• Chromatin immunoprecipitation (ChIP) to assess EZH2 binding to the ADRB2 promoter.
• Functional assays evaluating the impact of ADRB2 inhibition and overexpression on cell invasion and transformation.
• Analysis of ADRB2 expression in clinical prostate cancer samples.

Main Results:

• ADRB2 (Adrenergic Receptor, Beta-2) was identified as a novel EZH2 target gene.
• EZH2 directly represses ADRB2 expression by binding to its promoter.
• Inhibition of ADRB2 promotes cell invasion and transforms benign prostate epithelial cells.
• Overexpression of ADRB2 counteracts EZH2-mediated oncogenic effects.
• ADRB2 is significantly underexpressed in metastatic prostate cancer.
• Low ADRB2 expression in localized tumors predicts a poor clinical prognosis.

Conclusions:

• This study identifies ADRB2 as a critical EZH2 target, linking EZH2-mediated epigenetic repression to prostate cancer progression.
• ADRB2 functions as a tumor suppressor in prostate cancer, and its downregulation by EZH2 contributes to oncogenesis.
• The integration of diverse genomic data is a powerful strategy for discovering disease-related gene targets.